Research from Christopher Scott, for example, suggests that increasing ARNT expression may be a potential therapeutic approach in the transition from nonalcoholic fatty liver disease to steatohepatitis (Scott et al., 2019). This evidence concerns the gene ARNT and metabolic dysfunction-associated steatotic liver disease.